N/A N=265 Physician Radiation Exposure During Radial Access Cardiac Catheterization Using a RAD Board
Radiation Exposure to Operator
Primary: Operator Radiation Exposure — .65; .56 mSv
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=55 Radiation Exposure of ERCP Personnel at Different Standing Locations and Different Patient Positions.
Occupational Radiation Exposure
Primary: Effective Radiation Dose — 0.0307; 0.0192 mSv
N/A N=10 Dosimeter Location in Pain Physicians
RAD
Primary: Radiation Readings — 122.8; 158.8; 236.9 mREM
N/A N=170 Reduce Radiation Exposure in Fluoroscopic Interventions Evaluation
Cardiac Catheterization · Radiation Exposure
Primary: Radiation Dose to Primary Operator (RaySafe), Cardiac Catheterization — 18; 39 microsievert
N/A N=1,000 ATTENUATE (rAdpad proTecTion drapE iN redUcing rAdiaTion Exposure) Trial
Radiation Exposure
Primary: Operator Exposure (OE)/Dose Area Product (DAP) (uSv[Micro-Sieverts]/mGy[Milligray]*cm2) of the Proximal Operator — 6.41; 3.51 10,000 x uSv / mGy*cm^2
N/A N=197 Radioprotective Light-weight Caps in the Interventional Cardiology Setting
Occupational Exposure to Radiation
Primary: Radiation Attenuation in Percentage (%) — 12; 91.5; 97.1 Percentage
N/A N=20 Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation
Node Positive Breast Cancer
Primary: Cardiac MRI Parameters — 0; 0; 0; 0 number of patients
N/A N=6,700 Adult and Paediatric Patient Radiation Doses From Multidetector Row Computed Tomography Scans: a National Survey
Cancer
Primary: Value of Mean Volumetric Computed Tomography Dose Index (CTDI Vol) for Head CT Examinations. — 64; 28.7 mGy
N/A N=228 Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells
Coronary Artery Disease · Chest Pain
Primary: Number of Excess Double-strand DNA Break Foci Per Cell in Peripheral Blood Samples Post-imaging — 0.183; 0.159 gamma-H2AX foci in blood lymphocytes — p=<0.05
Phase 2 N=187 RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Breast Cancer
Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…
N/A N=864,080 CT DOSE Collaboratory
Ionizing Radiation Exposure · Quality Improvement
Primary: Change in Mean Effective Dose (ED) — -0.13; -0.81; -0.14; -0.26 Millisieverts (mSv)
N/A N=72 Breast Displacement and CT Radiation Dose
Computed Tomography · Radiation Dosage
Primary: Skin Entrance Radiation Dose During Computed Tomography (CT) — 1775; 1325; 625; 259 mrad
N/A N=268 Work Should Not Hurt You: Reduction of Hazardous Exposures in Small Businesses Through a Community Health Worker Intervention
Community Health Aides · Industrial Hygiene · Volatile Organic Compounds
Primary: Change in Volatile Organic Chemical Concentrations From Pre- to Post-Intervention — 2738; 3875; 523; 225 ppb
N/A N=543 Virtual Sun Safe Workplaces Ph II (SSW Works)
Skin Cancer · Occupational Exposure
Primary: Change From Baseline Employee Sun Protection Practices at 1 Year — 3.55; 3.30; 3.71; 3.46 score on a scale
N/A N=20 Normal Tissue Oxygenation Following Radiotherapy
Radiation Toxicity
Primary: Tissue Oxygenation — 62.5 mmHg — p=0.5
N/A N=1,472 Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Primary: Number of Participants With Second Primary Malignancies (SPM) — 24 Participants
N/A N=136 X-ray Dose Reduction in Electrophysiology
Arrhythmias, Cardiac
Primary: Cumulative Dose Area Product (DAP) Value — 8.8; 15.3 Gy*cm^2 — p=<0.0001
N/A N=45 Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
Prostate Cancer · Adenocarcinoma of the Prostate
Primary: Procedure Time — 30 minutes
Phase 1 N=6 Augmenting Flortaucipir Dosimetry Estimates
Alzheimer's Disease
Primary: Urine Analysis - Total Integrated Radioactivity Excreted in Urine — 0.1413 megabecquerel-hours per megabecquerel
N/A N=117 Heterotopic Ossification Prophylaxis
Acetabular Fracture · Heterotopic Ossification
Primary: Number of Participants With Severe HO Formation — 3; 9 Participants
Phase 1 N=15 A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Lymphoma, Follicular
Primary: Area Under the Curve (AUC) at 0 to 120, 0 to 168, and 0 to Infinity Hours — 1.04; 1.18; 1.39 %ID.h/mL
Phase 2 N=19 Radioactive Iodide Therapy for Pediatric Graves' Disease
Graves' Disease
Primary: Dosimetry Studies
Phase 2 N=13 SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
Rectal Cancer
Primary: Neoadjuvant Response (NAR) Score — 9.31 Calculated score
N/A N=12 Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
Non-Hodgkin's Lymphoma · Lymphoma
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 10; 2 participants
N/A N=77 A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: The Proportion of Patients for Whom the Intended Treatment Was Feasible — 70 Participants
N/A N=102 Rapid Stress/Rest Single-Day Tc-99m Sestamibi Myocardial Single Photon Emission Computed Tomography
Coronary Artery Disease
Primary: Myocardial Perfusion SPECT Image Quality 12 Minutes — 1; 0; 8; 3 participants
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
N/A N=34 Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study
Aortic Aneurysm · Contrast Induced Nephropathy · Aortic and Arterial Anomalies
Primary: Ascending Sinotubular Junction Measurement — 246.4; 287.5 Hounsfield units
N/A N=2,862 The Respiratory Protection Effectiveness Clinical Trial
Influenza · Respiratory Syncytial Viruses · Paramyxoviridae Infections
Primary: Protective Effects of N95 Respirators vs Medical Masks (MM) as Assessed by Number of Influenza A and B Events — 222; 204 number of influenza A and B events
N/A N=1,133 TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry
Breast Cancer
Primary: Number of Patients With Local Recurrence — 10 participants